CancerDrs

Cervical Cancer clinical trials in California

82 actively recruiting cervical cancer trials at 50 sites across California.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in California:
  • Kaiser Permanente-Bellflower — Bellflower, California
  • City of Hope Corona — Corona, California
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • Kaiser Permanente South Bay — Harbor City, California
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in California:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Stanford Cancer Institute Palo Alto — Palo Alto, California
  • University of California Davis Comprehensive Cancer Center — Sacramento, California
  • UC San Diego Medical Center - Hillcrest — San Diego, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in California:
  • Research Site — Duarte, California
  • Research Site — Fountain Valley, California
  • Research Site — Fullerton, California
  • Research Site — Irvine, California
  • Research Site — La Jolla, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…

Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Sites in California:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • University of California Los Angeles Westwood Cancer Center — Los Angeles, California
  • Stanford Medicine - Cancer Center — Palo Alto, California
  • Moores Cancer Center — San Diego, California
  • UCSF Head and Neck Surgery Cancer Program — San Francisco, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in California:
  • CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5037) — Irvine, California
  • University of California Irvine Medical Center ( Site 6006) — Orange, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in California:
  • University of California Los Angeles — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in California:
  • City of Hope Corona — Corona, California
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • City of Hope at Irvine Lennar — Irvine, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…

Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in California:
  • Research Site — La Jolla, California
  • Research Site — West Hollywood, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…

Sponsor: SOFIE
NCT ID: NCT07217704
Sites in California:
  • Helios CR Inc./RadNet — Cerritos, California
  • City of Hope National Cancer Center — Duarte, California
  • Hoag Memorial Hospital — Irvine, California
  • UCLA — Los Angeles, California
  • Stanford University — Stanford, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in California:
  • Tower Cancer Research Foundation — Beverly Hills, California
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California
  • Los Angeles General Medical Center — Los Angeles, California
  • USC / Norris Comprehensive Cancer Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in California:
  • USC / Norris Comprehensive Cancer Center — Los Angeles, California
  • Stanford Cancer Institute Palo Alto — Palo Alto, California
  • Sutter Medical Center Sacramento — Sacramento, California
  • University of California Davis Comprehensive Cancer Center — Sacramento, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it fi…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06029270
Sites in California:
  • Kaiser Permanente Dublin — Dublin, California
  • Kaiser Permanente-Fremont — Fremont, California
  • Kaiser Permanente Fresno Orchard Plaza — Fresno, California
  • Kaiser Permanente-Fresno — Fresno, California
  • Keck Medicine of USC Koreatown — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in California:
  • University of California Los Angeles Medical Center — Los Angeles, California
  • University of California, San Diego; Moores Cancer Center — San Diego, California
  • USOR Sansum Clinic — Santa Barbara, California
  • Providence Medical Foundation — Santa Rosa, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…

Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in California:
  • UCSD — La Jolla, California
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • Sharp Healthcare — San Diego, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in California:
  • Research Site 125 — Los Angeles, California
  • Research Site 133 — Los Angeles, California
  • Research Site 103 — Los Angeles, California
  • Research Site 128 — Santa Monica, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in California:
  • Ellison Clinic at Saint John's — Los Angeles, California
  • UCSF Medical Center at Mission Bay — San Francisco, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in California:
  • Avenzo Therapeutics Recruiting Site — Los Angeles, California
  • Avenzo Therapeutics Recruiting Site — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California:
  • Valkyrie Clinical Trials — Los Angeles, California
  • Los Angeles Cancer Network — Los Angeles, California
  • Pih Health Hematology Medical Oncology — Whittier, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain a…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06769698
Sites in California:
  • University of California Los Angeles — Los Angeles, California
  • Samuel Oschin Cancer Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in California:
  • VA Greater Los Angeles Healthcare System — Los Angeles, California
  • UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in California:
  • University of California, Davis Comprehensive Cancer Center — Sacramento, California
  • UCLA Hematology/Oncology - Santa Monica — Santa Monica, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in California:
  • Providence Medical Foundation (site 209) — Santa Rosa, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with adva…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in California:
  • UC Davis Comprehensive Cancer Center — Sacramento, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemip…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06980038
Sites in California:
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • Los Angeles General Medical Center — Los Angeles, California
  • USC / Norris Comprehensive Cancer Center — Los Angeles, California
  • UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
View on ClinicalTrials.gov →

Showing 25 of 82 trials with sites in California. See all cervical cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19